Certara (NASDAQ:CERT) Price Target Lowered to $20.00 at KeyCorp

Certara (NASDAQ:CERT) had its price target decreased by KeyCorp from $23.00 to $20.00 in a research note issued to investors on Thursday, Benzinga reports. KeyCorp currently has an overweight rating on the stock.

A number of other research analysts have also recently issued reports on the company. JMP Securities reiterated a market perform rating on shares of Certara in a research note on Wednesday, July 10th. Barclays lowered their price objective on Certara from $18.00 to $16.00 and set an equal weight rating for the company in a research note on Friday, June 28th. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Certara currently has an average rating of Hold and an average target price of $19.44.

Certara Trading Up 0.4 %

CERT opened at $15.18 on Thursday. The stock has a market cap of $2.44 billion, a PE ratio of -38.92, a PEG ratio of 5.23 and a beta of 1.52. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.27. The business has a 50 day moving average of $15.49 and a 200-day moving average of $16.65. Certara has a 52 week low of $11.81 and a 52 week high of $19.87.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The company had revenue of $96.65 million for the quarter, compared to analysts’ expectations of $94.48 million. Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. Equities research analysts predict that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Trading of Certara

Large investors have recently modified their holdings of the company. Mubadala Investment Co PJSC bought a new stake in shares of Certara in the fourth quarter worth $169,135,000. Franklin Resources Inc. grew its holdings in shares of Certara by 8.2% in the fourth quarter. Franklin Resources Inc. now owns 1,820,864 shares of the company’s stock worth $32,029,000 after acquiring an additional 138,682 shares during the period. Edmond DE Rothschild Holding S.A. grew its holdings in shares of Certara by 93.1% in the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 769,300 shares of the company’s stock worth $13,532,000 after acquiring an additional 370,820 shares during the period. Norges Bank bought a new stake in shares of Certara in the fourth quarter worth $14,262,000. Finally, Geneva Capital Management LLC grew its holdings in shares of Certara by 15.1% in the first quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after acquiring an additional 579,349 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.